Last reviewed · How we verify
(-)-Atropine (Hyoscyamine)
At a glance
| Generic name | Hyoscyamine |
|---|---|
| Sponsor | University of Kansas Medical Center |
| Drug class | hyoscyamine |
| Target | Muscarinic acetylcholine receptor M4 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Peptic Ulcer
- Gastric Secretion Control
- Functional Intestinal Disorders
- Irritable Bowel Syndrome
- Neurogenic Bladder and Bowel Disturbances
- Biliary and Renal Colic
- Acute Rhinitis
- Parkinsonism
- Anticholinesterase Poisoning
Common side effects
- Excessive dryness of the mouth
- Blurred vision
- Urinary difficulty
- Tachycardia
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PHASE4)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (-)-Atropine CI brief — competitive landscape report
- (-)-Atropine updates RSS · CI watch RSS
- University of Kansas Medical Center portfolio CI